Aerocrine and Chest sign distribution agreement

Chest will apply for market authorization of Niox Mino in Japan and then proceed to product launch. Niox Mino is a handheld device that in a couple of minutes gauges the inflammation in the airways, the underlying cause of asthma. Treatment of asthma focuses primarily on keeping the inflammation under control, which leads to fewer symptoms and less acute asthma exacerbations.

Paul de Potocki, CEO of Aerocrine, said: “The company has established relations and years of experience from selling medical devices to our prime target groups. Chest has also shown an impressive knowledge and enthusiasm for our product and method of inflammatory control.”